Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
27
datasets available to search
ShareScore release 0.9.0
Dataset results
27 results for “Preemptive therapy”
Data from: Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection
<p><strong>Background: </strong><em>Trypanosoma cruzi</em> and HIV coinfection can evolve with depression of cellular immunity and increased parasitemia. We applied quantitative PCR (qPCR) as a marker for preemptive antiparasitic treatment to avoid fatal Chagas disease reactivation and analyzed the outcome of treated cases.</p> <p><strong>Methodology:</strong> This mixed cross-sectional and longitudinal study included 171 Chagas disease patients, 60 coinfected with HIV. Of these 60 patients, ten showed Chagas disease reactivation, confirmed by parasites identified in the blood, cerebrospinal fluid, or tissues, 12 exhibited high parasitemia but no reactivation, and 38 had low parasitemia and no reactivation.</p> <p><strong>Results</strong>: We showed, for the first time, the success of the timely introduction of benznidazole in the non-reactivated group with high levels of parasitemia detected by qPCR and the absence of parasites in reactivated cases with at least 58 days of benznidazole. HIV+ and HIV+ without reactivation had a 4.0 – 5.1 higher chance of having parasitemia than HIV seronegative cases. A positive correlation was found between parasite and viral loads. Remarkably, treated <em>T. cruzi/</em>HIV-coinfected patients had 77.3% conversion from positive to negative parasitemia compared to 19.1% of untreated patients. Additionally, untreated patients showed ~13.6 times higher odds of having positive parasitemia in the follow-up period compared with treated patients. Treated and untreated patients showed no differences regarding the evolution of Chagas disease. The main factors associated with all-cause mortality were higher parasitemia, lower CD4 counts/µL, higher viral load, and absence of antiretroviral therapy.</p> <p><strong>Conclusion</strong>: We recommend qPCR prospective monitoring of <em>T. cruzi</em> parasitemia in HIV+ patients and point out the value of pre-emptive therapy for patients with temporary high parasitemia. In parallel, an early antiretroviral therapy introduction is advisable, aiming at viral load control, immune response restoration, and major survival. We also suggest an earlier antiparasitic treatment for all coinfected patients, followed by effectiveness analysis alongside antiretroviral therapy.</p>
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
ClinicalTrials.gov study NCT04308668. IPD Sharing: YES. Countries: 2. Publications: 12.
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
ClinicalTrials.gov study NCT02095951. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
ClinicalTrials.gov study NCT03115567. IPD Sharing: NO. Countries: 1. Publications: 1.
Data from: Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection
Open the record for dataset details and reuse information.
An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemo
ClinicalTrials.gov study NCT02354846. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
ClinicalTrials.gov study NCT04421664. IPD Sharing: YES. Countries: 2. Publications: 3.
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
ClinicalTrials.gov study NCT02985775. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
ClinicalTrials.gov study NCT03662087. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Preemptive Therapy of GVHD
ClinicalTrials.gov study NCT01994824. IPD Sharing: Not stated. Countries: 1. Publications: 1.
To Evaluate the Safety and Efficacy of Preemptive Administration of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema
ClinicalTrials.gov study NCT04991259. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
The Effects of Preemptive Multimodal Analgesic on Endodontic Pain Following Root Canal Therapy.
ClinicalTrials.gov study NCT07400471. IPD Sharing: NO. Countries: 1. Publications: 17.
PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS
ClinicalTrials.gov study NCT04416334. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of Preemptive Paracetamol and Ibuprofen on Headache and Myalgia in Patients After Electroconvulsive Therapy
ClinicalTrials.gov study NCT03783312. IPD Sharing: NO. Countries: 1. Publications: 1.
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
ClinicalTrials.gov study NCT06798909. IPD Sharing: NO. Countries: 1. Publications: 2.
Empirical Versus Preemptive Antifungal Therapy
ClinicalTrials.gov study NCT01288378. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov study NCT06138587. IPD Sharing: YES. Countries: 1. Publications: 0.
Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease
ClinicalTrials.gov study NCT04109300. IPD Sharing: NO. Countries: 1. Publications: 0.
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
ClinicalTrials.gov study NCT06075225. IPD Sharing: NO. Countries: 1. Publications: 0.
Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients
ClinicalTrials.gov study NCT01616121. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.